Alan K. Matsumoto

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Stanley Cohen, Mark C. Genovese, Ernest Choy et al. · Annals of the Rheumatic Diseases · 2017 · 182 citations · Full text

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Alan K. Matsumoto, Augustin Melian, David R. Mandel et al. · PubMed · 2002 · 135 citations

Spirituality, well‐being, and quality of life in people with rheumatoid arthritis

Susan J. Bartlett, Ralph L. Piedmont, Andrew Bilderback et al. · Arthritis Care & Research · 2003 · 123 citations

Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial

Alan K. Matsumoto, Najib Babul, Harry Ahdieh · Pain Medicine · 2005 · 118 citations · Full text

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six‐month, double‐blind, randomized, dose‐ranging study

Daniel E. Fürst, Kenneth G. Saag, Max Fleischmann et al. · Arthritis & Rheumatism · 2002 · 113 citations